TEM:NASDAQTempus AI, Inc. Analysis
Data as of 2026-06-17 - not real-time
$50.56
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Tempus AI, Inc. is trading well below its long‑term moving average while the short‑term averages sit beneath each other, indicating a bearish price bias. Technical signals such as a positive MACD histogram and a bullish MACD crossover suggest a potential short‑term rebound, reinforced by increasing volume and a double‑bottom pattern that is eyeing breakout resistance near the recent high.
On the fundamentals side, the company posts rapid revenue growth and strong gross margins, yet it remains unprofitable with negative earnings, a towering price‑to‑book multiple, and a balance sheet weighted heavily toward debt. Recent FDA clearances and strategic collaborations provide a catalyst narrative, but the high beta, elevated volatility, and sizable max drawdown underscore substantial risk. Investors should weigh the upside from the technical bounce and growth narrative against the deep valuation gap and financial fragility.
On the fundamentals side, the company posts rapid revenue growth and strong gross margins, yet it remains unprofitable with negative earnings, a towering price‑to‑book multiple, and a balance sheet weighted heavily toward debt. Recent FDA clearances and strategic collaborations provide a catalyst narrative, but the high beta, elevated volatility, and sizable max drawdown underscore substantial risk. Investors should weigh the upside from the technical bounce and growth narrative against the deep valuation gap and financial fragility.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Double‑bottom formation near support
- Bullish MACD crossover with positive histogram
- Rising volume indicating buying interest
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Revenue growth and strong gross margin profile
- Recent FDA approvals and expanding AI platform
- Target price upside from technical resistance breakout
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- High debt load and negative cash flow
- Elevated valuation multiples relative to earnings
- Long‑term potential in AI‑driven precision medicine
Key Metrics & Analysis
Financial Health
Revenue Growth36.10%
Profit Margin-22.20%
P/E Ratio-474.0
ROE-81.58%
ROA-9.07%
Debt/Equity316.65
P/B Ratio21.8
Op. Cash Flow$-185743008
Free Cash Flow$-55760000
Industry P/E24.7
Technical Analysis
TrendBearish
RSI52.5
Support$42.62
Resistance$54.75
MA 20$48.77
MA 50$49.83
MA 200$64.54
MACDBullish
VolumeIncreasing
Fear & Greed Index92.13
Valuation
Target Price$66.53
Upside/Downside31.59%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta2.55
Volatility74.56%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.